Psomagen, Inc. (KOSDAQ: A950200)
Health Care · Biotechnology · US
₩4,055.00
+39.35% today · +2.9% 1Y
Psomagen, Inc. (KOSDAQ: A950200) operates in the Biotechnology industry within the Health Care sector. The company is valued at $56.28M.
Over the last twelve months the share price has gained 2.9%, trading between 2.38K and 4.69K.
Tweenvest scores Psomagen, Inc. across four factors: quality 56/100, value 86/100. Its strongest factor is value.
A950200 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $56.28M
- Revenue (TTM)
- $39.88M
- P/E
- —
- EPS
- -79.24
- Dividend yield
- —
- Beta (5Y)
- -0.22
- 52-week high
- ₩4,690.00
- 52-week low
- ₩2,380.00
- Avg volume (3M)
- —
- Shares outstanding
- 19.24M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.